---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-125872"
form_type: "8-K"
ticker: "GKOS"
cik: "0001192448"
company_name: "GLAUKOS Corp"
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:32:55.039952+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Glaukos receives FDA approval for iDose TR; 2024 revenue guidance $350-$360M

## Summary
- FDA approved iDose TR (travoprost intracameral implant) for reducing IOP in OHT or OAG; launch expected late Q1 2024.
- Phase 3 trials randomized 1,150 subjects; iDose TR showed non-inferiority to timolol at 3 months (IOP reduction 6.6-8.4 mmHg).
- 81% of iDose TR subjects were free of topical IOP-lowering medications at 12 months; 98% subject retention at 12 months.
- Wholesale acquisition cost set at $13,950 per implant; Glaukos launches iDose Your Dose charitable donation initiative.
- Reaffirms 2023 net sales guidance of $307-$310M; introduces 2024 preliminary guidance of $350-$360M.

## SEC filing metadata
- accession: 0001104659-23-125872
- form_type: 8-K
- ticker: GKOS
- cik: 0001192448
- company_name: GLAUKOS Corp
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1192448/000110465923125872/0001104659-23-125872-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1192448/000110465923125872/tm2332871d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-125872
- JSON: https://secwatch.observer/filing/0001104659-23-125872.json
- Plain text: https://secwatch.observer/filing/0001104659-23-125872.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.